Stratification of Biologic Therapies for Rheumatoid Arthritis (RA) by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Etanercept; Tocilizumab
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms (STRAP)-EU

Most Recent Events

10 Jan 2021 Status changed from active, no longer recruiting to completed.
11 Dec 2020 Planned End Date changed from 19 Feb 2020 to 9 Jan 2021.
20 May 2019 New source identified and integrated ISRCTN: Current Controlled Trials

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight